Manufacturing / Pharmaceutical Preparations
IMMUNIC, INC.
IMUX
$8.22
+$0.66 (+8.70%)
Price as of Oct 9, 2026 19:21 UTC
220 M
Market Cap (Micro Cap)
Nov 11
Next Earnings
Technical Signals
as of Oct 7
Bearish
0 of 7
Trend
- Above 20-day average $9.78
- Above 50-day average $11.72
- Above 200-day average $11.07 · -31.1%
- Moving averages stacked Not aligned
Momentum
- Golden cross (50/200) —
- Momentum cross (20/50) Down · 19d ago
Volume
- Below-average volume 0.9x avg
Price & Trend
Daily candles with EMA 20, SMA 50. Drag to zoom.
Options Heat Map
Delta-risk grid for IMUX options across strikes and expirations. Hover any cell for full Greeks.
Loading option chain data...
Insider Trades
9 buys
0 sells
| Date | Insider | Title | Type | Shares | Value | Since Trade |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | BVF PARTNERS L P/IL | Grant | 25,370 | $0 | -25.3% | |
| Sep 16, 2026 | Nagel Robert Thorvald | Grant | 25,370 | $0 | -25.3% | |
| Aug 06, 2026 | Ridloff Elena | Grant | 50,740 | $0 | -48.0% | |
| Jul 05, 2026 | Skerjanec Simona | Grant | 25,370 | $0 | -49.1% | |
| Jul 05, 2026 | Congleton Jon | Grant | 25,370 | $0 | -49.1% | |
| Jul 05, 2026 | PHILLIPS BARCLAY A | Grant | 25,370 | $0 | -49.1% | |
| Jul 05, 2026 | Neermann Joerg | Grant | 25,370 | $0 | -49.1% | |
| Jul 05, 2026 | Rudick Richard Alan | Grant | 25,370 | $0 | -49.1% | |
| May 22, 2026 | Lundgren Erik | Grant | 1,000,000 | $0 | -42.1% | |
| May 22, 2026 | Lundgren Erik | Other | 1,000,000 | $0 | -42.1% |
Earnings History
| Date | Quarter | EPS Est. | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Aug 05, 2026 | Q2 2026 | -$1.22 | |||
| May 13, 2026 | Q1 2026 | -$0.93 | |||
| Mar 31, 2026 | Q1 2026 | -$0.93 | -$1.08 | -16.0% | Miss |
| Dec 31, 2025 | Q4 2025 | -$0.96 | -$0.70 | +27.1% | Beat |
| Sep 30, 2025 | Q3 2025 | -$1.71 | -$1.30 | +23.9% | Beat |
| Jun 30, 2025 | Q2 2025 | -$1.68 | -$2.00 | -18.8% | Miss |
| Mar 31, 2025 | Q1 2025 | -$0.24 | -$0.25 | -3.6% | Miss |
Track IMUX with ThetaPal
Get insider trade alerts, AI portfolio analysis, and options roll recommendations for IMUX and your entire portfolio.